If you or a loved one has been diagnosed with uveal (ocular) melanoma, there is a chance that the cancer will spread to another part of your body. This is called metastatic uveal melanoma.

Malignant melanoma is the fastest-growing and 7th ... depending on tumor invasiveness and metastasis. Evidence of metastatic spread should routinely be sought when examining patients.

The following is a summary of “Application of interpretable machine learning algorithm to predict lymph node metastasis in cutaneous malignant melanoma,” published in the April 2025 issue of ...

Sep. 16, 2024 — Long-term data from a landmark international trial show about half of patients with metastatic melanoma treated with a combination of immune checkpoint inhibitors survive cancer ...

Malignant melanoma (MM) is among the most lethal cutaneous neoplasms, frequently tied to metastasis and poor outcomes. Neural cell adhesion molecule L1 (L1CAM) is a protein that has been associated ...

Replimune Group, Inc.'s RP1 + OPDIVO for advanced melanoma gains FDA Priority Review. PDUFA date: July 22, 2025. Read more on ...

HealthDay News — For patients with unresectable metastatic uveal melanoma (mUM), the drug/device combination melphalan/hepatic delivery system (HDS) is efficacious and has a favorable risk-benefit ...

Researchers at Baylor College of Medicine, Texas Children's Hospital, the Hospital for Sick Children in Toronto and ...

Thus, for over 50 years now, scientists have been on a quest to identify which malignant mutations ... alleles of APOE can enhance or suppress melanoma metastasis. To find out whether breast ...

Neoadjuvant pepinemab treatment shows potential to enhance immune response and improve survival in metastatic melanoma and head and neck cancer. Vaccinex, Inc. announced promising findings ...

Toripalimab is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and to induce PD-1 receptor internalization (endocytosis ...

positivity and a patient's personal risk of melanoma recurrence and/or metastasis. By integrating tumor biology with clinical and pathologic factors using a validated proprietary algorithm ...